Antimalarial resistance unlikely to explain U.K. artemether-lumefantrine failures

Gelijkaardige items

• No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine.
  door: van Vugt, M, et al.
  Gepubliceerd in: (1999)
• Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
  door: Liusheng Huang, et al.
  Gepubliceerd in: (2017-01-01)
• Potential Antimalarial Activity of Artemether/Lumefantrine/Doxycycline: A Study in Mice Infected with Plasmodium berghei
  door: Udeme Owunari Georgewill, et al.
  Gepubliceerd in: (2022-02-01)
• Pharmaceutical quality of antimalarial drugs: quinine sulfate and Artemether/Lumefantrine tablets sold on Bukavu Market
  door: Aladin Ombeni Mahano, et al.
  Gepubliceerd in: (2021-06-01)
• Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial
  door: Peto, TJ, et al.
  Gepubliceerd in: (2022)